Prof Kaye WilliamsBSc PhD FSB

Chair Experimental Therapeutics

Full contact details
View graph of relations

Overview

Outside of running a successful research group and teaching highly motivated students on the MPharm programme, many of my academic leadership and management roles within the University of Manchester are focused upon the promotion and development of research. Specific contributions are made via roles in the following groups:

  • Pre-clinical lead for oncology imaging within the Manchester Cancer Research Centre. To establish, direct and implement the pre-clinical non-invasive imaging strategy within the MCRC. Leadership has resulted in procurement of new preclinical PET/CT scanner, development of strategic research interaction within imaging science with industrial partners (for example GE, AstraZeneca, Lilly) and kick-started oncology-based projects within MCRC across different research areas.
  • Co-chair of the University of Manchester Preclinical Imaging Executive (PrIME)
  • Head of Pharmaceutical Sciences, Manchester Pharmacy School

My additional roles focus on equality and diversity and in staff training and development. I chaired the Athena Swan Self Assessment team in Manchester Pharmacy School and was the MPS representative on the previous faculty's Equality and Diversity committee. I am staff training and development lead for Pharmacy and work with colleagues towards developing cases for promotion both within and outwith my division. 

 

Biography

Professor Kaye Williams is the Leader of the Hypoxia and Therapeutics Group within the Manchester Pharmacy School. Kaye joined the Experimental Oncology division in November 1996 upon completion of PhD studies. Following back-to-back Research Associate and Research Fellow positions funded by the Medical Research Council, she gained a tenured Senior Lecturer position in January 2006, was promoted to Reader in July 2010 and Chair in Experimental Therapeutics and Imaging in August 2012. Her group currently focuses upon the tumour microenvironment, investigating therapeutic targets, vascular biology and molecular interactions. She also leads pre-clinical imaging development within the Manchester Cancer Research Centre. Her research is funded via the MRC, BBSRC, EPSRC, Cancer Research UK and the European Union, with commercial funding via collaboration with a number of Pharmaceutical Companies.

Kaye was awarded the British Association for Cancer Research/AstraZeneca Frank Rose Young Scientist Award in 2005, and was elected a Fellow of the Society of Biology in 2010.

Qualifications

  • 1997 - PhD Faculty of Medicine - University of Manchester
  • 1993 - BSc (Hons) Molecular Biology - First Class, School of Biological Sciences, University of Manchester

Memberships of committees and professional bodies

  • Research Council of  Norway; Panel Reviewer and Chair Panel 9: Independent Projects in Medicine, Health Sciences and Biology (FRIMEDBIO) 2016-
  • Committee member Association for Radiation Research 2016-
  • National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Research (CTRad) Working Group: mamber of workstream 1 (basic science)
  • Chair of the NCRI CTRad RadCom initiative 2016-
  • Member of the NCRI CTRad Executive Group 2010-
  • Fellow of the Society of Biology 2010-
  • Trustee of the LH Gray Memorial Trust (2006-). Current secretary and treasurer. Chair 2016 onwards.

Member of

  • British Association for Cancer Research
  • European Association for Cancer Research
  • American Association for Cancer Research
  • Association of Radiation Research
  • Radiation Research Society

Research Networks and Beacons

Biology, Medicine and Health (BMH) Domains

Related information